Conference Coverage
Conference Coverage
Will tirzepatide slow kidney function decline in type 2 diabetes?
Compared to insulin glargine, tirzepatide was associated with significantly less new-onset macroalbuminuria in patients with T2D at high...
Conference Coverage
Pancreatic involvement in COVID-19: What do we know?
“Our data identify the human pancreas as a target of SARS-CoV-2 infection and suggest that pancreatic beta cell involvement could contribute to...
Conference Coverage
Exenatide linked to less hyperglycemia after stroke
The diabetes drug may offer better control than insulin for hyperglycemia, a common condition following stroke that leads to worse outcomes.
Conference Coverage
Vegan diet helps shed pounds but doesn’t dint diabetes
A vegan diet most likely led to weight loss because it is “associated with a reduced calorie intake due to a lower content of fat and higher...
Conference Coverage
Calorie counting and exercise ‘of limited value’ for obesity weight loss
“Our survey results indicate that, while the majority of adults with obesity are actively trying to reduce their weight, using a variety of...
Conference Coverage
New research holds promise for fighting obesity, says expert
A growing understanding of adipose tissue as an endocrine organ responsible for weight control opens avenues for treatment, she says.
Conference Coverage
Combo of SGLT2 inhibitor + GLP-1 RA boosts diabetes survival
Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class...
Conference Coverage
Better survival in older cancer patients who take metformin
“It is important to explore optimal dosages that significantly improve cancer outcomes to boost anticancer effect.”
Conference Coverage
High comorbidity rate seen before osteoarthritis diagnosis
More than 40 medical conditions were positively associated with having a new diagnosis of osteoarthritis in a large, nested case-control study.
Conference Coverage
Empagliflozin rapidly improves acute heart failure symptoms in hospitalized patients
Empagliflozin showed symptomatic benefits in patients hospitalized for acute heart failure after 2 weeks in a secondary analysis from the EMPULSE...